E-viri
Recenzirano
Odprti dostop
-
Grob, Tim; Sanders, Mathijs A; Vonk, Christian M; Kavelaars, Franҫois G; Rijken, Melissa; Hanekamp, Diana W; Gradowska, Patrycja L; Cloos, Jacqueline; Fløisand, Yngvar; van Marwijk Kooy, Marinus; Manz, Markus G; Ossenkoppele, Gert J; Tick, Lidwine W; Havelange, Violaine; Löwenberg, Bob; Jongen-Lavrencic, Mojca; Valk, Peter J M
Journal of clinical oncology, 02/2023, Letnik: 41, Številka: 4Journal Article
The applicability of -internal tandem duplications ( -ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of -ITD during relapse. Here, we comprehensively investigated the impact of next-generation sequencing (NGS)-based -ITD MRD detection on treatment outcome in a cohort of patients with newly diagnosed AML in relation to established prognostic factors at diagnosis and other MRD measurements, ie, mutant and multiparameter flow cytometry. In 161 patients with de novo -ITD AML, NGS was performed at diagnosis and in CR after intensive remission induction treatment. -ITD MRD status was correlated with the cumulative incidence of relapse and overall survival (OS). NGS-based -ITD MRD was present in 47 of 161 (29%) patients with AML. Presence of -ITD MRD was associated with increased risk of relapse (4-year cumulative incidence of relapse, 75% -ITD MRD 33% no -ITD MRD; < .001) and inferior OS (4-year OS, 31% -ITD MRD 57% no -ITD MRD; < .001). In multivariate analysis, detection of -ITD MRD in CR confers independent prognostic significance for relapse (hazard ratio, 3.55; < .001) and OS (hazard ratio 2.51; = .002). Strikingly, -ITD MRD exceeds the prognostic value of most generally accepted clinical and molecular prognostic factors, including the -ITD allelic ratio at diagnosis and MRD assessment by NGS-based mutant detection or multiparameter flow cytometry. NGS-based detection of -ITD MRD in CR identifies patients with AML with profound risk of relapse and death that outcompetes the significance of most established prognostic factors at diagnosis and during therapy, and furnishes support for -ITD as a clinically relevant biomarker for dynamic disease risk assessment in AML.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.